BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Imcheck closes $84M series C round for gamma-delta T-cell activating antibody
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Imcheck closes $84M series C round for gamma-delta T-cell activating antibody
June 13, 2022
By
Cormac Sheridan
No Comments
Imcheck Therapeutics SAS raised €80 million (US $83.5 million) in a series C round to maintain the momentum of its lead development program, ICT-01, an immunostimulatory antibody that activates gamma-delta T cells.
BioWorld
Financings
Cancer
Series C